Keros Therapeutics Enters Material Definitive Agreement
Ticker: KROS · Form: 8-K · Filed: Apr 18, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
Related Tickers: KROS
TL;DR
Keros Therapeutics (KROS) signed a big deal, filing an 8-K today.
AI Summary
Keros Therapeutics, Inc. announced on April 17, 2025, that it has entered into a material definitive agreement. The company, focused on pharmaceutical preparations, filed an 8-K report detailing this agreement. Further details regarding the nature of the agreement and its financial implications are expected to be disclosed.
Why It Matters
This filing indicates a significant development for Keros Therapeutics, potentially impacting its future operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this initial filing warrants a medium risk assessment.
Key Numbers
- 001-39264 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1173868 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- April 17, 2025 (date) — Date of earliest event reported
- 001-39264 (company) — SEC File Number
- 811173868 (company) — IRS Employer Identification No.
- Lexington, Massachusetts (location) — Principal executive offices location
FAQ
What is the nature of the material definitive agreement entered into by Keros Therapeutics?
The filing states that Keros Therapeutics, Inc. entered into a material definitive agreement on April 17, 2025. Specific details of the agreement are not provided in this initial 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 17, 2025.
What is Keros Therapeutics' principal executive office address?
Keros Therapeutics' principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics?
The SEC file number for Keros Therapeutics is 001-39264.
What is the standard industrial classification for Keros Therapeutics?
Keros Therapeutics falls under the Standard Industrial Classification code 2834, which is for Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 18, 2025 regarding Keros Therapeutics, Inc. (KROS).